These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23490176)

  • 21. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation.
    Zhang W; Kim R; Quintini C; Hashimoto K; Fujiki M; Diago T; Eghtesad B; Miller C; Fung J; Tan A; Menon KV; Aucejo F
    Liver Transpl; 2015 Jan; 21(1):101-11. PubMed ID: 25283528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HCV histological recurrence and survival following liver transplantation in patients with and without hepatocellular carcinoma.
    De Martin E; Senzolo M; Boninsegna S; Guido M; Masier A; Germani G; Tomat S; Brolese A; Neri D; Cillo U; Gambato M; Russo FP; Farinati F; Burra P
    Transplant Proc; 2008; 40(6):1974-5. PubMed ID: 18675104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival of children after liver transplantation for hepatocellular carcinoma.
    Baumann U; Adam R; Duvoux C; Mikolajczyk R; Karam V; D'Antiga L; Chardot C; Coker A; Colledan M; Ericzon BG; Line PD; Hadzic N; Isoniemi H; Klempnauer JL; Reding R; McKiernan PJ; McLin V; Paul A; Salizzoni M; Furtado ESB; Schneeberger S; Karch A;
    Liver Transpl; 2018 Feb; 24(2):246-255. PubMed ID: 29222922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
    Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S
    Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft.
    Yi NJ; Suh KS; Lee HW; Shin WY; Kim J; Kim W; Kim YJ; Yoon JH; Lee HS; Lee KU
    Liver Transpl; 2009 May; 15(5):496-503. PubMed ID: 19399732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival.
    Groeschl RT; Hong JC; Christians KK; Turaga KK; Tsai S; Pilgrim CH; Gamblin TC
    HPB (Oxford); 2013 Oct; 15(10):794-802. PubMed ID: 23782341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid fibrosis and significant histologic recurrence of hepatitis C after liver transplant is associated with higher tumor recurrence rates in hepatocellular carcinomas associated with hepatitis C virus-related liver disease: a single center retrospective analysis.
    Vasavada BB; Chan CL
    Exp Clin Transplant; 2015 Feb; 13(1):46-50. PubMed ID: 25654412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of model for end-stage liver disease score on long-term survival following liver transplantation for hepatocellular carcinoma.
    Roma J; Balbi E; Pacheco-Moreira L; Zyngier I; Araujo A; Agoglia L; Steinbruck K; Velaverde LG; Martinho JM
    Transplant Proc; 2012 Oct; 44(8):2423-7. PubMed ID: 23026611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular Carcinoma in the Setting of Chronic Hepatitis B Virus Infection: Tumor Recurrence and Survival Rates After Liver Transplantation.
    Dugum M; Hanouneh I; Lopez R; Aucejo F; Eghtesad B; Zein N
    Transplant Proc; 2015; 47(6):1939-44. PubMed ID: 26293077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Donor factors similarly impact survival outcome after liver transplantation in hepatocellular carcinoma and non-hepatocellular carcinoma patients.
    Salgia RJ; Goodrich NP; Marrero JA; Volk ML
    Dig Dis Sci; 2014 Jan; 59(1):214-9. PubMed ID: 24077924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Living donor liver transplantation for hepatocellular carcinoma.
    Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
    Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
    Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
    Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma.
    Abdel-Wahab M; Sultan AM; Fathy OM; Salah T; Elshobary MM; Elghawalby NA; Yassen AM; Elsarraf WM; Elsaadany MF; Zalatah K
    Hepatogastroenterology; 2013; 60(128):1847-53. PubMed ID: 24719918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?
    Moya A; Berenguer M; Aguilera V; Juan FS; Nicolás D; Pastor M; López-Andujar R; Rayón M; Orbis F; Mora J; De Juan M; Carrasco D; Vila JJ; Prieto M; Berenguer J; Mir J
    Liver Transpl; 2002 Nov; 8(11):1020-7. PubMed ID: 12424715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
    Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
    Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
    Taniguchi M
    Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma.
    de Ataide EC; Garcia M; Mattosinho TJ; Almeida JR; Escanhoela CA; Boin IF
    Transplant Proc; 2012 Oct; 44(8):2438-40. PubMed ID: 23026614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.